Thomas Osterholt
Overview
Explore the profile of Thomas Osterholt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhne L, Knobl P, Eller K, Thaler J, Sperr W, Gleixner K, et al.
Blood
. 2024 Jun;
144(14):1486-1495.
PMID: 38838300
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency. Caplacizumab, an anti-von Willebrand...
2.
Cukoski S, Osterholt T, Suarez V, Hackl M, Grundmann F, Burst V, et al.
Eur J Endocrinol
. 2023 Jun;
188(6):526-535.
PMID: 37307578
Objective: Achieving recommended targets of sodium correction is challenging to physicians treating hyponatraemia. Plasma sodium has to be increased effectively, yet overcorrection must be prevented. This is often hampered by...
3.
Osterholt T, Todorova P, Kuhne L, Ehren R, Weber L, Grundmann F, et al.
Sci Rep
. 2023 Apr;
13(1):6980.
PMID: 37117201
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are glomerulopathies associated with nephrotic syndrome. Primary forms of these diseases are treated with various regimes of immunosuppression. Frequently relapsing or...
4.
Vial F, McGurrin P, Osterholt T, Ehrlich D, Iannacone S, Donkervoort S, et al.
Mov Disord Clin Pract
. 2023 Apr;
10(4):646-651.
PMID: 37070061
Background: The concept of a myopathy with associated tremor ("myogenic tremor") in humans has been previously described for specific (Myosin-Binding Protein C) variants. Here we report for the first time...
5.
Volker L, Kaufeld J, Balduin G, Merkel L, Kuhne L, Eichenauer D, et al.
J Thromb Haemost
. 2023 Jan;
21(3):559-572.
PMID: 36696206
Background: The von Willebrand factor-directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety....
6.
Osterholt T, Gloistein C, Todorova P, Becker I, Arenskrieger K, Melka R, et al.
J Am Heart Assoc
. 2022 Sep;
11(17):e025229.
PMID: 36056721
Background Acute kidney injury (AKI) is a major risk factor for chronic kidney disease and increased mortality. Until now, no compelling preventive or therapeutic strategies have been identified. Dietary interventions...
7.
Diefenhardt P, Osterholt T, Brinkkotter P
Dtsch Med Wochenschr
. 2022 Mar;
147(6):332-336.
PMID: 35291039
Advances in basic and clinical research have improved our understanding of the pathomechanisms underlying nephrotic syndrome caused by minimal change disease (MCD) and focal and segmental glomerulosclerosis (FSGS). These advances...
8.
Koehler F, Fu C, Spath M, Hoyer-Allo K, Bohl K, Gobel H, et al.
Transl Res
. 2022 Feb;
244:32-46.
PMID: 35189406
Caloric Restriction (CR) extends lifespan and augments cellular stress-resistance from yeast to primates, making CR an attractive strategy for organ protection in the clinic. Translation of CR to patients is...
9.
McGurrin P, Vial F, Osterholt T, Norato G, Khan I, Haubenberger D, et al.
Mov Disord Clin Pract
. 2022 Feb;
9(2):191-197.
PMID: 35146059
Background: Essential tremor is a common movement disorder, characterized by 4-12 Hz tremor of the hands and arms that can affect many activities of daily living. It has been reported...
10.
Kuhne L, Kaufeld J, Volker L, Wendt R, Schonermarck U, Hagele H, et al.
J Thromb Haemost
. 2022 Jan;
20(4):951-960.
PMID: 35000278
Background: The anti-von Willebrand factor (VWF) nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of...